The World Health Organization will recommend using weight-loss drugs to treat obesity in adults, according to draft guidance from the agency that urged countries to take the condition seriously as a chronic disease.

Wegovy-maker Novo Nordisk will cut 9,000 jobs in a restructuring, aiming to save 8 billion Danish crowns ($1.26 billion) annually, the company said on Wednesday, as it battles rising pressure from main U.S. rival Eli Lilly .

Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly's rival medicines Mounjaro and Zepbound in a real-world comparison of overweight and obese patients with cardiovascular disease but not diabetes.

Analogs of the pancreatic peptide hormone amylin are making strides in obesity as developers zoom in on oral drugs that can emulate or even improve on injectable GLP-1 agonists while avoiding muscle l...

Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk's Wegovy.

Eli Lilly (NYSE:LLY) announced positive Phase 3 ATTAIN-1 trial results for orforglipron, its investigational oral GLP-1 receptor agonist, in treating obesity. The once-daily pill demonstrated significant weight loss, with participants taking the highest dose (36mg) losing an average of 27.3 lbs (12.4%) compared to 2.2 lbs (0.9%) with placebo over 72 weeks.The trial, involving 3,127 adults, met all primary and secondary endpoints. At the highest dose, 59.6% of participants lost ≥10% body weight, and 39.6% lost ≥15%. The drug also showed improvements in cardiovascular risk markers, including a 47.7% reduction in hsCRP levels. The safety profile aligned with injectable GLP-1 therapies, with mainly gastrointestinal side effects.Lilly plans to submit orforglipron for regulatory review by year-end and is preparing for a global launch.

Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, after a major profit warning and new CEO announcement last week wiped some $95 billion of value from the company's stock.

Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic.

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to revive sales and a share price hit by worries the maker of weight-loss drug Wegovy is falling behind in a race it started.

Union Pacific said on Tuesday it would buy smaller rival Norfolk Southern in an $85 billion deal, to create the nation's first coast-to-coast freight rail operator and reshape the movement of goods from grains to autos across the country.

Danish pharmaceutical giant Novo Nordisk on Tuesday cuts its full-year sales and profit guidance.